Daily Newsletter

25 August 2023

Daily Newsletter

25 August 2023

Signal: NHS whistle-blower policy questioned following Letby conviction

In light of the conviction of nurse Lucy Letby for murder, doctors are calling for a revisit of whistle-blowing policies.

Isaac Hanson August 25 2023

Following the conviction of Lucy Letby for the murder of seven babies and the attempted murder of six more, questions have been raised about the whistle-blower policy of the UK’s National Health Service (NHS).

It has been reported that doctors at the Countess of Chester hospital raised concerns about Letby’s behaviour as early as 2015, the same year that the killings began. However, they were ignored by managers, and, after Letby’s parents threatened to refer these doctors to the General Medical Council, they were forced to apologise to her.

This has understandably led to calls for reform in the NHS, particularly around whistle-blowing laws. Norman Lamb, a former member of UK parliament and current chair of an NHS trust, has raised the case of a previous NHS whistle-blower in conjunction.

https://twitter.com/normanlamb/status/1694409521425265055

The UK’s medical licencing board has, in fact, updated its good practice guidelines for the first time in ten years this week and part of that package is a revision in whistle-blower recommendations to encourage a culture in which staff feel safe reporting concerns.

These guidelines will not come into force until 2024, and, while enforceable to a degree – the General Medical Council (GMC) can remove a doctor’s licence to practice – they still require reporting of such behaviours in order to act. Some in the field argue that these still fail to address the root of the problem.

https://twitter.com/EmergMedDr/status/1694073868237832221

 Our signals coverage is powered by GlobalData’s Thematic Engine, which tags millions of data items across six alternative datasets — patents, jobs, deals, company filings, social media mentions and news — to themes, sectors and companies. These signals enhance our predictive capabilities, helping us to identify the most disruptive threats across each of the sectors we cover and the companies best placed to succeed. 

Multiple Myeloma (MM) pipeline is dominated by CAR-T cells

The success of CAR-Ts in MM has fueled R&D investment into this class of therapy, with more CAR-Ts in development than all other cell and gene therapy classes combined. The approval of the autologous CAR-T cell therapies Abecma and Carvykti sees the CAR-T pipeline mostly constituted of autologous drugs. However, there are also multiple allogeneic CAR-Ts in the pipeline, with these therapies having an “off-the-shelf” advantage over autologous therapies.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close